<div id="readability-page-1"><p>Omeros (NASDAQ:OMER - Get Free Report) will likely be announcing its  Q4 2025 results after the market closes on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.57) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.</p><h2>Omeros Stock Down 5.0%</h2><ul><li>Breakout Momentum Plays You Need to Know About</li></ul><p>Shares of NASDAQ:OMER opened at $11.44 on Tuesday. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $17.65. The firm's 50 day moving average price is $12.42 and its 200 day moving average price is $8.50. The stock has a market cap of $811.10 million, a price-to-earnings ratio of -5.66 and a beta of 2.45. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities research analysts have recently weighed in on OMER shares. HC Wainwright raised their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 8th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Omeros in a research report on Thursday, January 22nd. D. Boral Capital  reiterated a &#34;buy&#34; rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. Finally, Wall Street Zen downgraded shares of Omeros from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, January 10th. One equities research analyst  has rated the stock with a Strong Buy rating, two have assigned  a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat, Omeros  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $40.33.</p><p><b>Read Our Latest Analysis on Omeros</b></p><h2>Insiders Place Their Bets</h2><p>In other Omeros news, CAO David J. Borges sold 30,000 shares of the firm's stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 12.90% of the stock is currently owned by corporate insiders. </p><h2>Institutional Investors Weigh In On Omeros</h2><p>Several hedge funds have recently made changes to their positions in the business. State of Wyoming acquired a new position in  Omeros in the 4th quarter valued at about $25,000.  Caitong International Asset Management Co. Ltd purchased a new position in shares of  Omeros in the 4th quarter valued at approximately $33,000.  Arax Advisory Partners grew its stake in shares of  Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 1,894 shares during the last quarter.  Osaic Holdings Inc. increased its holdings in shares of  Omeros by 34.6% in the fourth quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company's stock valued at $130,000 after purchasing an additional 1,938 shares during the period.  Finally, Abel Hall LLC purchased a new stake in shares of  Omeros during the fourth quarter worth approximately $176,000. Institutional investors and hedge funds own  48.79% of the company's stock. </p><h2>Omeros Company Profile</h2> (Get Free Report)<p>Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.  </p><p>Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.</p><h2>See Also</h2><ul><li>Five stocks we like better than Omeros</li><li>Elon Musk already made me a “wealthy man”</li><li>Elon’s Secret AI Partner?</li><li>Silver $500? The &#34;Deficit Math&#34; says it's possible.</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Omeros Right Now?</h2><p>Before you consider Omeros, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.</p><p>While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Omeros (NASDAQ:OMER) is set to announce its Q4 2025 earnings on March 3, with analysts predicting a loss of $0.57 per share. The stock is currently down 5.0%, trading at $11.44, with a market cap of $811.10 million. Recent analyst ratings include a "buy" from HC Wainwright with a price target of $40.00, while Weiss Ratings maintains a "sell" rating. Institutional investors hold 48.79% of the company, which focuses on developing therapeutics for inflammation and central nervous system disorders. Omeros's first FDA-approved product is Omidria® for cataract surgery.</p>

Market Beat

SPDR S&P Biotech

Health Care Select Sector SPDR

iShares Global Healthcare

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

VG Health

iShares US Pharma

Ark Genomic Revolution ETF

Omeros

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Omeros (OMER) Expected to Announce Earnings on Tuesday